Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer

INTRODUCTION: Transurethral resection of bladder tumor with subsequent BCG immunotherapy is the current gold standard in the treatment of high risk and some medium-risk non-muscle invasive bladder cancer. Clinical factors like stage, grade, age and gender are well-know predictors of progression to m...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamkiewicz, Mateusz, Bryniarski, Piotr, Kowalik, Maksymilian, Burzyński, Bartłomiej, Rajwa, Paweł, Paradysz, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033152/
https://www.ncbi.nlm.nih.gov/pubmed/33842371
http://dx.doi.org/10.3389/fonc.2021.655000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033152/
https://www.ncbi.nlm.nih.gov/pubmed/33842371
http://dx.doi.org/10.3389/fonc.2021.655000

Ejemplares similares